Published in Nature on May 28, 1992
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol (2012) 1.63
Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol (2007) 1.55
Translocation of aquaporin-containing vesicles to the plasma membrane is facilitated by actomyosin relaxation. Biophys J (2007) 1.47
Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest (2000) 1.41
β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function. Kidney Int (2016) 1.38
X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest (1993) 1.31
Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A (1995) 1.31
Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet (1994) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol (2013) 1.26
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J (1995) 1.19
Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem J (1998) 1.17
Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene. J Clin Invest (2000) 1.15
Inactivation of Notch signaling in the renal collecting duct causes nephrogenic diabetes insipidus in mice. J Clin Invest (2009) 1.12
Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet (1992) 1.10
Structure, function, and phylogeny of [Arg8]vasotocin receptors from teleost fish and toad. Proc Natl Acad Sci U S A (1994) 1.10
Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J (1996) 1.10
Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. J Clin Invest (1995) 1.09
AKI associated with cardiac surgery. Clin J Am Soc Nephrol (2014) 1.08
Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev (2013) 1.06
Cloning and identification of an oxytocin/vasopressin-like receptor and its ligand from insects. Proc Natl Acad Sci U S A (2008) 1.03
Heterogeneous AVPR2 gene mutations in congenital nephrogenic diabetes insipidus. Am J Hum Genet (1994) 1.02
Discovery of a novel insect neuropeptide signaling system closely related to the insect adipokinetic hormone and corazonin hormonal systems. J Biol Chem (2010) 1.02
X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet (1992) 1.02
Sequence-specific "gene signatures" can be obtained by PCR with single specific primers at low stringency. Proc Natl Acad Sci U S A (1994) 1.01
Rat renal arcade segment expresses vasopressin-regulated water channel and vasopressin V2 receptor. J Clin Invest (1996) 0.98
Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res (2010) 0.97
Structure, characterization, and expression of the rat oxytocin receptor gene. Proc Natl Acad Sci U S A (1995) 0.96
Spatially restricted G protein-coupled receptor activity via divergent endocytic compartments. J Biol Chem (2013) 0.92
Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem J (1996) 0.91
Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol (2008) 0.90
Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest (1993) 0.89
Mitochondrial metabolism of a hydroperoxide to free radicals in human endothelial cells: an electron spin resonance spin-trapping investigation. Biochem J (1994) 0.88
Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling. Kidney Int (2008) 0.88
Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2. Clin Exp Nephrol (2012) 0.87
Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS One (2012) 0.87
Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V). PLoS One (2013) 0.86
Acute rejection modulates gene expression in the collecting duct. J Am Soc Nephrol (2008) 0.86
Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line. Br J Pharmacol (1996) 0.84
Aquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus-update and epidemiology. Clin Kidney J (2012) 0.84
Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression. Biochem J (2001) 0.84
Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor. Proc Natl Acad Sci U S A (1996) 0.84
Congenital nephrogenic diabetes insipidus presented with bilateral hydronephrosis: genetic analysis of V2R gene mutations. Yonsei Med J (2006) 0.84
Vasopressin and oxytocin in control of the cardiovascular system. Curr Neuropharmacol (2013) 0.84
Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev Med Chem (2008) 0.83
Homology between neurohypophyseal hormone receptors. Biochem J (1993) 0.82
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes. Br J Pharmacol (2000) 0.82
Nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr (2012) 0.82
Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors. Biochem J (1996) 0.82
Discovery of sea urchin NGFFFamide receptor unites a bilaterian neuropeptide family. Open Biol (2015) 0.81
Deletion of the V2 vasopressin receptor gene in two Chinese patients with nephrogenic diabetes insipidus. BMC Genet (2006) 0.80
The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest (1996) 0.80
Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study. Eur J Pediatr (2015) 0.80
Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format. Front Endocrinol (Lausanne) (2014) 0.79
Analysis of a novel AVPR2 mutation in a family with nephrogenic diabetes insipidus. Int J Clin Exp Med (2010) 0.79
Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem (2006) 0.79
Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-. Br J Pharmacol (2005) 0.79
Dynamic regulation and dysregulation of the water channel aquaporin-2: a common cause of and promising therapeutic target for water balance disorders. Clin Exp Nephrol (2013) 0.78
Thioacylation is required for targeting G-protein subunit G(o1alpha) to detergent-insoluble caveolin-containing membrane domains. Biochem J (2001) 0.78
Functions of vasopressin and oxytocin in bone mass regulation. Proc Natl Acad Sci U S A (2015) 0.77
Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation. Br J Pharmacol (1999) 0.77
Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand. Endocrinology (2011) 0.77
Spilanthol from Acmella Oleracea Lowers the Intracellular Levels of cAMP Impairing NKCC2 Phosphorylation and Water Channel AQP2 Membrane Expression in Mouse Kidney. PLoS One (2016) 0.76
A case of nephrogenic diabetes insipidus with a novel missense mutation in the AVPR2 gene. Pediatr Nephrol (2007) 0.76
Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin. Am J Physiol Renal Physiol (2012) 0.76
Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking. Mol Endocrinol (2016) 0.76
A Rare Case of Congenital Diabetes Insipidus. Front Med (Lausanne) (2015) 0.75
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol (2001) 0.75
Nephrogenic diabetes insipidus: an X chromosome-linked dominant inheritance pattern with a vasopressin type 2 receptor gene that is structurally normal. Proc Natl Acad Sci U S A (1994) 0.75
Congenital nephrogenic diabetes insipidus with a novel mutation in the aquaporin 2 gene. Biomed Rep (2014) 0.75
Protective effect of a vasopressin-1 selective antagonist, OPC-21268, against ethanol-induced damage of the rat gastric wall. Dig Dis Sci (1999) 0.75
A novel AVPR2 gene mutation of X-linked congenital nephrogenic diabetes insipidus in an Asian pedigree. J Int Med Res (2016) 0.75
Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A (1999) 3.85
Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet (1995) 3.29
Rotator-cuff changes in asymptomatic adults. The effect of age, hand dominance and gender. J Bone Joint Surg Br (1995) 3.25
The GTP-binding protein, Go, regulates neuronal calcium channels. Nature (1987) 3.24
Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology (1983) 2.30
Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature (1992) 2.30
Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature (1991) 2.15
Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res (1991) 1.99
Infections in recipients of liver homografts. N Engl J Med (1968) 1.92
Epidemiology of blindness in Nepal. Bull World Health Organ (1985) 1.91
Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med (1994) 1.80
Multiple neurological abnormalities in mice deficient in the G protein Go. Proc Natl Acad Sci U S A (1998) 1.70
Cefotaxime-hydrolysing beta lactamases in Morganella morganii. Eur J Clin Microbiol Infect Dis (1999) 1.67
Exposure-response analysis of risk of respiratory disease associated with occupational exposure to chrysotile asbestos. Occup Environ Med (1997) 1.63
Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem (1993) 1.55
Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J (2001) 1.47
Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol (2001) 1.47
Localization and pharmacological characterization of high affinity binding sites for vasopressin and oxytocin in the rat brain by light microscopic autoradiography. Brain Res (1988) 1.46
Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem (1999) 1.45
Evaluation of the Andromas matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli. J Clin Microbiol (2012) 1.45
Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest (2000) 1.41
[Cholinesterase inhibitor therapy in long term care settings]. Rev Med Interne (2006) 1.39
How to minimize interaction between phenytoin and enteral feedings: two approaches. Nutr Clin Pract (1996) 1.38
Effects of preschool screening for vision and hearing on prevalence of vision and hearing problems 6-12 months later. Lancet (1980) 1.37
Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J Biol Chem (1989) 1.35
A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. Mol Pharmacol (1998) 1.34
Subunit II of cytochrome c oxidase in Chlamydomonad algae is a heterodimer encoded by two independent nuclear genes. J Biol Chem (2000) 1.34
The development of the distal femur Less Invasive Stabilization System (LISS). Injury (2001) 1.34
X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest (1993) 1.31
beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem (1997) 1.30
Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet (1994) 1.30
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett (1998) 1.27
An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers. Occup Environ Med (2007) 1.26
Crystalline silica exposure and lung cancer mortality in diatomaceous earth industry workers: a quantitative risk assessment. Occup Environ Med (2001) 1.25
125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol (1988) 1.25
Sources of uncertainty in dose-response modeling of epidemiological data for cancer risk assessment. Ann N Y Acad Sci (1999) 1.21
Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical membrane of renal cells. Am J Physiol Renal Physiol (2001) 1.21
An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem (2001) 1.20
Degradation of inositol 1,3,4,5-tetrakisphosphates by porcine brain cytosol yields inositol 1,3,4-trisphosphate and inositol 1,4,5-trisphosphate. Biochem Biophys Res Commun (1988) 1.20
PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest (2000) 1.19
The cost of cataract surgery in a public health eye care program in Nepal. Health Policy (1996) 1.17
Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density. Mol Pharmacol (1994) 1.16
Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor. Br J Pharmacol (1998) 1.16
Different types of ADP-ribose protein bonds formed by botulinum C2 toxin, botulinum ADP-ribosyltransferase C3 and pertussis toxin. Biochem Biophys Res Commun (1988) 1.16
Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J Neurosci (2001) 1.14
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS (1998) 1.13
The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem (1995) 1.11
Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet (1992) 1.10
Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J Clin Immunol (1995) 1.10
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett (1996) 1.09
Aquaporin-2 expression in primary cultured rat inner medullary collecting duct cells. Am J Physiol (1998) 1.09
Correlation of meniscal T2* with multiphoton microscopy, and change of articular cartilage T2 in an ovine model of meniscal repair. Osteoarthritis Cartilage (2013) 1.09
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol (1998) 1.06
Adipocyte plasma membranes contain two Gi subtypes but are devoid of Go. FEBS Lett (1988) 1.06
A functional genomic study to identify differential gene expression in the preterm and term human myometrium. Biol Reprod (2003) 1.05
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol (1996) 1.04
A heterotrimeric G protein of the Gi family is required for cAMP-triggered trafficking of aquaporin 2 in kidney epithelial cells. J Biol Chem (1998) 1.04
Role of G proteins in calcium channel modulation. Annu Rev Physiol (1990) 1.04
Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine (2006) 1.04
Pharmacological characterization of two specific binding sites for neurohypophyseal hormones in hippocampal synaptic plasma membranes of the rat. EMBO J (1985) 1.03
Immunological localization of the GTP-binding protein Go in different tissues of vertebrates and invertebrates. Mol Pharmacol (1987) 1.03
Angiotensin II-induced stimulation of voltage-dependent Ca2+ currents in an adrenal cortical cell line. EMBO J (1988) 1.02
An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Mol Endocrinol (1994) 1.02
Exposure to crystalline silica, silicosis, and lung disease other than cancer in diatomaceous earth industry workers: a quantitative risk assessment. Occup Environ Med (2002) 1.02
Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother (2010) 1.01
Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function. Mol Pharmacol (1996) 1.01
The role of nucleoside-diphosphate kinase reactions in G protein activation of NADPH oxidase by guanine and adenine nucleotides. Eur J Biochem (1988) 1.01
Differential sensitivity to guanine nucleotides of basal and insulin-stimulated glucose transporter activity reconstituted from adipocyte membrane fractions. FEBS Lett (1989) 1.01
Keratin-mediated resistance to stress and apoptosis in simple epithelial cells in relation to health and disease. Biochem Cell Biol (2001) 1.00
The mechanisms of aquaporin control in the renal collecting duct. Rev Physiol Biochem Pharmacol (2000) 0.99
Identification of receptor-activated G proteins with photoreactive GTP analog, [alpha-32P]GTP azidoanilide. Methods Enzymol (1991) 0.99
A single negatively charged residue affects the orientation of a membrane protein in the inner membrane of Escherichia coli only when it is located adjacent to a transmembrane domain. J Biol Chem (1999) 0.99
Oxytocin receptors in the central nervous system. Distribution, development, and species differences. Ann N Y Acad Sci (1992) 0.99
The predominant aciduric microflora of root-caries lesions. J Dent Res (2001) 0.98
Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol (2000) 0.97
Tissue distribution of beta 1- and beta 2-subunits of regulatory guanine nucleotide-binding proteins. Biochim Biophys Acta (1989) 0.97
The molecular basis of nephrogenic diabetes insipidus. J Mol Med (Berl) (1998) 0.97
Activation of protein kinase C by cis- and trans-fatty acids and its potentiation by diacylglycerol. Biochem Biophys Res Commun (1988) 0.96
Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology (1995) 0.95
Clonal chondroprogenitors maintain telomerase activity and Sox9 expression during extended monolayer culture and retain chondrogenic potential. Osteoarthritis Cartilage (2008) 0.95
Disruption of the G(i2) alpha locus in embryonic stem cells and mice: a modified hit and run strategy with detection by a PCR dependent on gap repair. Transgenic Res (1993) 0.95
Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C-terminus. FEBS Lett (1998) 0.95
Osmolality and solute composition are strong regulators of AQP2 expression in renal principal cells. Am J Physiol Renal Physiol (2002) 0.95
[3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol (1988) 0.95
Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. FEBS Lett (2001) 0.94
DNA synthesis in developing sea urchins: role of a DNA-nuclear membrane complex. Nat New Biol (1973) 0.94
Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization. J Biol Chem (1992) 0.93
[3H]vasopressin binding to rat hippocampal synaptic plasma membrane. Kinetic and pharmacological characterization. FEBS Lett (1983) 0.93
Identification of Rab3-, Rab5a- and synaptobrevin II-like proteins in a preparation of rat kidney vesicles containing the vasopressin-regulated water channel. FEBS Lett (1995) 0.93